IL-STATS
25.7.2017 09:32:10 CEST | Business Wire | Press release
STATS, the global leader in sports data and intelligence, has launched an innovative new product, STATS Edge. STATS Edge is a search and analytics application powered by artificial intelligence that enables football teams to instantly find video clips and analyse complex patterns in a game with more speed and accuracy than ever before. With the power of AI-driven analytics at their fingertips, analysts can instantly and effectively assess in detail a team’s strengths and weaknesses while focusing on various aspects of the game.
Drawing on STATS’ rich history in data collection and analysis, STATS Edge will utilise data from the Premier League, Championship, La Liga, Ligue de Football Professionnel, Serie A, Bundesliga, Qatar Stars League, Champions League and more. STATS Edge will initially be available in five languages.
STATS Edge unifies football data and video through an easy-to-use and intuitive user interface, developed in close partnership with top English, French and Spanish clubs through a design-thinking methodology. This allows everyone in the football club – from match analysts to the manager – to analyse, annotate and share insights on the same platform.
“It’s increasingly difficult for clubs to process and analyse all the relevant data points available and distil complex information into timely, accurate insight,” said Kenneth Fuchs, STATS’ CEO. “On top of that, traditional analytics don’t always speak the visual language of players and coaches. We’ve applied computer vision and artificial intelligence to bring new levels of context and efficiency to teams already using video for their match preparations. It’ll save them time, allow them to develop proprietary results, and help get them the information to make, share and track the best decisions.”
The STATS Edge search engine allows managers and analysts to use their football vocabulary within a search box to find relevant video clips in seconds across entire leagues or competitions, regardless of the complexity of their queries. They can link a multitude of events and playing styles to search, which allows the execution of more than 1,000 search combinations.
The ability to search across players, teams, styles, set plays and more using natural language is a substantial step forward in accessing complex tracking data in a simple interface. For example, STATS Edge lets users quickly find and retrieve all of a team’s counter attacks which led to goals, a player’s key events such as shots or crosses in the last five games, or passes into a custom defined zone on the pitch. This use of analytics also helps clubs assess the value of a transfer target in order to reach a fully informed decision before making an investment.
Once clips are identified, STATS’ proprietary Exemplar Search, built by its award-winning data science team, can instantly find clips of similar plays at the click of a button. By using AI algorithms, the platform reads the combination of player and ball trajectories as well as events in any clip to retrieve the respective Exemplar Search results.
STATS Edge further builds on the power of AI to provide exciting and intuitive analytical features, starting with set plays and transitions. By dynamically specifying a zone on the field and other variables, the manager and analyst instantly accesses in-depth analysis and all corresponding videos. For example, in set-play analysis of an opponent, one can identify target zones and link them to the most dangerous players and their shooting or goal efficiency. In transition analysis, one can analyse the key players involved, as well as their most typical behaviour after winning or losing the ball.
About STATS
STATS is the global leader in sports intelligence. Trusted by the world’s most innovative teams, leagues and brands seeking the winning edge at the intersection of sports and technology, STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customisable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry today to enhance both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSInsightsUK .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005426/en/
Contact:
STATS
Dennis Dougherty, 847-583-2680
ddougherty@stats.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom